Last updated: February 22, 2026
What is NDC 00574-0279?
NDC 00574-0279 refers to Vaxneuvance, GlaxoSmithKline’s pneumococcal vaccine. Approved by the FDA in August 2021, Vaxneuvance is indicated for the prevention of invasive pneumococcal disease (IPD), pneumonia, and acute otitis media in adults aged 18 years and older[^1].
Market Landscape
Market Size and Growth
The pneumococcal vaccine market is projected to reach $7.5 billion globally by 2027, expanding at a compound annual growth rate (CAGR) of 6.2% from 2022 to 2027[^2].
Key drivers include:
- Increasing incidence of pneumococcal disease among older adults.
- Growing awareness and vaccination rates.
- Expansion into adult indications, increasing the target population.
Key Competitors
- Prevnar 13 (Pfizer): Dominant in pediatric and adult markets; 2022 sales exceeded $6 billion[^3].
- Pneumovax 23 (Merck): Widely used for adults; projected to remain significant due to established use and reimbursement.
- Vaxneuvance: Market entry has introduced competition, especially in broader age indications.
Adoption and Prescribing Patterns
- Adoption initially slow, given brand recognition of Prevnar 13 and Pneumovax 23.
- Physicians are increasingly adopting Vaxneuvance for its broader serotype coverage (15-valent vs. Pneumovax 23’s 23-valent, but with different coverage profiles).
- Reimbursement policies are vital; Medicare and Medicaid coverage impact uptake.
Pricing Analysis
Current Pricing
- Vaxneuvance: List price approximately $150-$180 per dose (single dose).
- Prevnar 13: Approximately $165-$200 per dose.
- Pneumovax 23: Around $100-$150 per dose.
Pricing varies with procurement volume, reimbursement negotiations, and patient assistance programs.
Reimbursement and Market Access
Medicare Part B covers pneumococcal vaccines, with payment rates around $150-$200 per dose (based on Medicare Part B fee schedules). Coverage policies influence ordering patterns:
- Vaxneuvance faces reimbursement challenges relative to longstanding products.
- Manufacturers offer patient assistance programs reducing out-of-pocket costs.
Price Trends and Projections
- Prices for pneumococcal vaccines have largely stabilized but tend to decline over time due to increased competition.
- With Vaxneuvance entering the market, generic and biosimilar entries are unlikely soon due to vaccine complexity and patent protections.
- Contract negotiations with payers could reduce effective prices approximately 10-15% over the next 2 years.
Potential Price Changes
- Year 1 (2023-2024): Stable list prices, with slight discounts negotiated by payers.
- Year 2-3: Price reductions of 10-15% possible, driven by market pressures and expanded usage.
Regulatory and Policy Impact
- The CDC’s Advisory Committee on Immunization Practices (ACIP) recommends pneumococcal vaccination for adults aged 65+ and high-risk groups.
- Updated guidelines emphasizing broader use could accelerate uptake.
- Policy changes aiming to reduce vaccine costs could pressure pricing.
Key Markets and Opportunities
| Regional Market |
Estimated Value (2022) |
Growth Rate |
Key Factors |
| United States |
$3.5 billion |
6.2% CAGR |
High adult vaccination rates, Medicare reimbursement influence |
| European Union |
$1.8 billion |
5.8% CAGR |
Robust healthcare systems, vaccination campaigns |
| Asia-Pacific |
$1.2 billion |
7.0% CAGR |
Growing awareness, expanding healthcare infrastructure |
Opportunities include expanding indications, particularly in immunocompromised and elderly populations, and competitive pricing strategies.
Summary
Vaxneuvance, as a newer entrant in the pneumococcal vaccine market, currently holds a limited but growing market share. Its pricing remains competitive but faces pressure from established vaccines. The trajectory indicates slight price decreases over the coming years, with market penetration driven by guideline endorsements and reimbursement policies.
Key Takeaways
- The global pneumococcal vaccine market is expanding, with an expected $7.5 billion valuation by 2027.
- Vaxneuvance’s initial pricing aligns with existing vaccines but faces market entry challenges.
- Price reductions of 10-15% are plausible within 2 years due to increasing competition and payer negotiations.
- Adoption hinges on guideline updates and reimbursement policies; large healthcare systems are slow adopters.
- Opportunities exist in expanding indications and regional markets, notably Asia-Pacific.
FAQs
Q1: How does Vaxneuvance differ from Prevnar 13?
Vaxneuvance covers 15 serotypes, whereas Prevnar 13 covers 13. It is approved for broader adult use and has a different immunogenic profile, targeting different serotypes relevant to adult populations.
Q2: What factors influence the pricing of pneumococcal vaccines?
Pricing is influenced by manufacturing complexity, market competition, reimbursement policies, and negotiated discounts with payers.
Q3: What is the outlook for vaccine prices over the next 3 years?
Prices are expected to decline by 10-15% as market competition increases and payer negotiations become more favorable to cost containment.
Q4: Which regions are poised for the highest growth?
Asia-Pacific is expected to see the highest CAGR at 7%, driven by rising awareness and expanding healthcare coverage.
Q5: How do reimbursement policies impact market uptake?
Reimbursement levels directly influence provider willingness to prescribe and administer vaccines, impacting overall market penetration.
References
[1] FDA. (2021). Vaxneuvance approval announcement.
[2] Grand View Research. (2022). Pneumococcal vaccine market size, trends, and forecasts.
[3] EvaluatePharma. (2022). Annual pharmaceutical sales data.
